China Slump Slows Herbalife, Potential There Drives Outlook
Executive Summary
Herbalife executives note firm's results from China, off 21.7% including impact of currency exchange, drag on its overall results.But they emphasize firm is prepared in China to rebound from slowdown regulators imposed and exceed growth of ts other regions.
You may also be interested in...
US Q3 Consumer Health Earnings Preview: Helm Changes, Supply Challenges, Separation Plan
July-September results for sales of OTC drugs, supplements and personal care products will come with CEO leaving J&J and P&G, a new leader for Perrigo Americas, Bausch Health likely offering Bausch + Lomb separation details and a cloud of rising costs related to supplies.
Herbalife’s China Growth Plan Includes Expediting Business Licensing, Tighter Hiring Standards
Four-point China initiative also includes implementing sales strategy already a fixture in other regions, nutrition clubs with daily meetings. China's April-June results compelled firm to lower earnings forecast.
Herbalife Pays $123M To Resolve Criminal, Civil Charges From US Investigation Of China Business
Direct seller pays fines in settlements with SEC and DoJ on bribery and other charges but two former executives for its operations in China still face criminal charges alleging violations of the Foreign Corrupt Practices Act. They have not been arrested and have remained at large since being charged in November 2019.